Dr. Herbst on Nivolumab for NSCLC
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discuses the impact of the FDA's approval of nivolumab's for the treatment of squamous non-small cell lung cancer.
Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the impact of the FDA approval of nivolumab for the treatment of squamous non-small cell lung cancer.
Now that nivolumab has been approved and studies have shown it improves survival, the focus should shift to how to integrate it with other therapies, says Herbst.
Researchers should investigate how nivolumab combines with chemotherapy, targeted therapies and other immunotherapies. Understanding how nivolumab can best be used will be very important for the future treatment of NSCLC, says Herbst.
<<<
